Trogenix CEO Ken Macnamara (L) and CSO Steve Pollard
Exclusive: Scottish biotech debuts with ‘Trojan horse’ platform for cancer
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.